Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14091445 | 1.00 | ACE (0.41) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL20154135 | 0.82 | ANPEP (0.35) | ACEENPEPANPEP | |
| SCHEMBL13213426 | 0.79 | ACE (0.39) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL24494714 | 0.79 | ACE (0.39) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL27250345 | 0.79 | ACE (0.39) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL18435207 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL22696774 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL24153005 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL18880094 | 0.78 | TGFBR1 (0.33) | — | |
| SCHEMBL20622862 | 0.77 | KDM4E (0.63) | ACEKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209382-A1 | NANOPARTICLES AND BIOTEMPLATES WITH TUNABLE LENGTH AND METHODS OF MANUFACTURING THE SAME | UNIVERSITY OF DELAWARE | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209382-A1 | NANOPARTICLES AND BIOTEMPLATES WITH TUNABLE LENGTH AND METHODS OF MANUFACTURING THE SAME | RNGTT, HBS1L, BROX | ACE 1147/4885KDM4E 3151/4885MAPT 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.